BIOMARIN PHARMACEUTICAL INC (BMRN) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US09061G1013
BIOMARIN PHARMACEUTICAL INC financials
| Fiscal year | 2025 |
|---|---|
| Revenue | 3.22 bn USD |
| Gross profit | 2.50 bn USD |
| Operating income | 409.48 m USD |
| EBIT | 418.48 m USD |
| Net income | 348.90 m USD |
| Diluted EPS – continuing operations | 1.80 USD |
Full history since 1998, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About BIOMARIN PHARMACEUTICAL INC
BioMarin Pharmaceutical Inc., a biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Pacific, and internationally. The company's products include VIMIZIM, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; VOXZOGO, a once daily injection analog of c-type natriuretic peptide (CNP) for the treatment of achondroplasia; NAGLAZYME, a recombinant form of N- acetylgalactosamine 4-sulfatase for patients with MPS VI; and PALYNZIQ, a PEGylated recombinant phenylalanine (Phe) ammonia lyase enzyme delivered through subcutaneous injection to reduce blood Phe concentrations. It also develops BRINEURA, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; ALDURAZYME, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase; and KUVAN, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria, an inherited metabolic disease. The company's products under development include BMN 333, a longer-acting CNP for the treatment of multiple growth disorders, such as achondroplasia and hypochondroplasia; and BMN 351, an oligonucleotide for the treatment of duchenne muscular dystrophy. It serves specialty pharmacies, hospitals, non-U.S. government agencies, distributors, and pharmaceutical wholesalers. The company has license and collaboration agreements with and Ares Trading S.A. The company was incorporated in 1996 and is based in San Rafael, California.
More stocks
- ALTEOGEN Inc (196170.KQ)
- U-Haul Holding Co /NV/ (UHAL)
- Hormel Foods (HRL)
- Beazley PLC (BEZ.L)
- TTM TECHNOLOGIES INC (TTMI)
- Jack Henry & Associates (JKHY)
- Astra International Tbk PT (PTAIY)
- Nova Ltd (NVMI)
- Unicharm Corp (8113.T)
- Tongling Nonferrous Metals Group Co Ltd (000630.SZ)
- Trelleborg AB (TREL B.ST)
- SERVICE CORP INTERNATIONAL (SCI)
Not investment advice. All data without warranty, price as of 14.10.2026. Details in the risk notice.